Single Bispecific Antibody for Non-Hodgkin Lymphoma May Reduce Time and Costs
Key Takeaways:
- A survey of oncology practice providers indicated that using a single bispecific antibody (BsAb) for both relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) and follicular lymphoma (FL) could reduce administrative complexity and streamline care.
- In hypothetical scenarios involving community and academic practices, the first year of single BsAb adoption accumulated time savings of 3110 hours and 10 626 hours, respectively, translating to monetized savings of $278 013 and $963 074, respectively.
- Improvements in operational efficiency were primarily driven by less time spent on medication preparation, onboarding, insurance navigation, initial treatment planning and ongoing adjustments, and adverse event (AE) management.
The number of US Food and Drug Administration (FDA)-approved medications for non-Hodgkin lymphoma (NHL) has grown in recent years. While multiple therapies offer more alternatives for patients, they also increase provider administrative burden as practices manage paperwork and insurance interactions for each medication.
Researchers conducted a mixed-methods study to assess the impact of using a single BsAb to treat both RR DLBCL and FL compared to using a separate treatment for each disease.
Study Methods and Outcomes
The study had 3 phases. The first phase consisted of interviews with 18 US oncology practice providers to identify operational tasks that may become more efficient when 1 BsAb is used to treat multiple diseases.
The second phase included a national survey of providers to quantify the impact of single treatment usage on staffing time and resource use.
In the third phase, researchers used survey results to estimate cost and time savings among oncology practices within the first year of single therapy adoption.
Savings were analyzed from 3 perspectives: community practice, academic practice, and combined network (all survey respondents).
Provider Characteristics
Among the 105 oncology providers who completed the survey, 43 were physicians, 42 were advanced practice providers or nurses, and 20 were pharmacists. Most providers belonged to academic practices rather than community settings, 65 vs 40, respectively.
The average oncology experience among participants was 13 years, and many respondents reported treating 50 to 100 or 100 to 250 patients with DLBCL or FL each year. Most practices had previously prescribed chimeric antigen receptor (CAR) T-cell therapy or any BsAb.
Single Treatment for Multiple Diseases Could Improve Operational Efficiency
According to survey participants, domains that might see the most improvement through single treatment adoption are onboarding, insurance navigation and financial aid, medication preparation, and treatment planning.
Hypothetical scenarios in which community and academic practices treated 100 patients (61 with DLBCL and 39 with FL) with a single BsAb estimated time savings of 3110 hours and 10 626 hours, respectively, during the first year of adoption. A hypothetical combined network saw a reduction of 7826 hours.
Adoption of single BsAb use also resulted in monetized time savings of $278 013 for the community practice, $963 074 for the academic practice, and $715 300 for the combined network. These savings project per-patient costs of $2643, $8941, and $6703, respectively.
Bulk purchasing and reduced medication wastage resulted in total direct cost savings of $525 600 for the community practice, $1 210 611for the academic practice, and $962 886 for the combined network.
Operational efficiencies were driven by reduced time spent on medication preparation, ongoing treatment plan adjustments, and AE management. The academic practice had greater savings, indicating more complex administrative procedures.
Implications for Managed Care
These findings suggest that using a single BsAb for multiple disease states may streamline care and reduce administrative burden among oncology practices and providers.
For example, epcoritamab has FDA approval for both DLBCL and FL. In addition to providing significant clinical benefits, prescribing it for both diseases could improve operational workflows and reduce procedural complexity.
The authors noted that “the time saved by onboarding just one drug instead of two can be redirected toward implementation of other new therapies.”
Reference
Graff T, Bains Chawla S, Jun M, et al. Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US. Future Oncol. 2026;22(6):719-727. doi:10.1080/14796694.2026.2636559


